profit from every $100 of sales.
$0$100
Nakamoto
$5.79-7.36% today
+763.7% in 1 year
1-year low $0.441-year high $20.32
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Nakamoto sold, what it kept, and what it did with the cash.
Sales went from $3.79 million in 2022 to $1.82 million in 2025, with -$52.2 million of profit last year.
SalesProfit
Nakamoto vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nakamoto | No profit yet | ||
 Concentra Group Holdings Parent | 32.5× · Expensive | ||
 Hims & Hers Health | 36.0× · Expensive | ||
 Envista | 84.1× · Very expensive | ||
 Beta Bionics | No profit yet |
AI analysis
An AI analyst reads Nakamoto's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4 | 4 | 3 | 2 | |
| 4 | 4 | -1 | -9 | |
| -3 | -2 | -3 | -21 | |
| -2 | -1 | -3 | -45 | |
| -3 | -2 | -4 | -52 | |
| -17.25 | -10.98 | -26.80 | -10.40 | |
| 96.0% | 94.0% | -31.0% | -508.8% | |
| -71.1% | -43.0% | -123.1% | -1,160.1% | |
| -67.1% | -42.9% | -133.0% | -2,867.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1 | 1 | 4 | 731 |
| Cash | 0 | 1 | 2 | 23 |
| Total debt | 0 | 1 | 0 | 210 |
| Total liabilities | 1 | 1 | 1 | 216 |
| 0 | -0 | 3 | 514 | |
| 0 | 0 | 0 | 5 | |
| -259.9% | -233.7% | -94.1% | -4.9% | |
| -666.8% | 1,492.0% | -140.9% | -10.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -0 | -0 | -3 | -24 | |
| 0 | 0 | 0 | 0 | |
| -0 | -0 | -3 | -24 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 0 | |
| 2 | 0 | 0 | 2 |
Valuation
- –
- 289.5×
- –
- 0.1×
- 56.9×
- –
- –
- -22.9%
- -50.4%
- 0.0%
Profitability
- -508.8%
- -1,160.1%
- -2,867.6%
- -1,496.5%
- -6.2%
- -142.3%
- -84.8%
- -46.7%
- -9.7%
- 0.0%
Growth
- −21.7%
- –
- −20,616.1%
- –
- +141.5%
Financial health
- –
- 0.57
- 33.8%
- -3.2×
- 0.25
- 0.25
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 29%of 952
Bottom 4%of 870
Bottom 3%of 985
What analysts expect
- Average price target
- $8.00
- Range
- $8.00 – $8.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.38 | -0.01 | −7,500.0% |
| Mar 30, 2026 | -0.05 | -0.02 | −150.0% |
| Nov 19, 2025 | -0.06 | -0.01 | −500.0% |
| Aug 5, 2025 | -0.34 | -0.35 | +2.9% |
| May 8, 2025 | -0.17 | – | – |
| Mar 28, 2025 | -0.17 | – | – |
| Nov 12, 2024 | -0.17 | – | – |
| Aug 13, 2024 | -0.26 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
7No pass
Benjamin Graham
50No pass
Philip Fisher
38No pass
Peter Lynch
32No pass
Joel Greenblatt
0No pass
Charlie Munger
38No pass
Terry Smith
32No pass
Questions about Nakamoto
Is Nakamoto a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nakamoto AI analysis
What does Nakamoto do?
Nakamoto Inc. develops and invests in a global portfolio of Bitcoin-native companies. The company provides commercial and financial infrastructure for the capital markets. The company was formerly known as Kindly MD, Inc. and change its name to Nakamoto Inc. in January 2026. It is in Medical - Equipment & Services.
Does Nakamoto pay a dividend?
No. Nakamoto does not pay a dividend at the moment; in 2025 it returned $320,404 to shareholders by buying back its own shares.
Is Nakamoto stock halal?
No. Nakamoto does not pass our halal screen: its debt is 203% of its market value, at or above the 33% limit. How we check
How has Nakamoto stock done over the past year?
Up 763.7% over the past twelve months, to $5.79. It traded between $0.44 and $20.32 and is 71.5% below its high.
Who are Nakamoto's competitors?
The largest listed companies in the same industry are Concentra Group Holdings Parent, Hims & Hers Health, Envista and Beta Bionics. The peers table on this page compares their profit, growth and price with Nakamoto's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.